{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:54:55Z","timestamp":1793656495926,"version":"4.5.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacc.2023.03.390","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T14:37:43Z","timestamp":1683556663000},"page":"1902-1914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy of Empagliflozin in Patients With\u00a0Heart\u00a0Failure Across Kidney Risk\u00a0Categories"],"prefix":"10.1016","volume":"81","author":[{"given":"Javed","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Jamal","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Gergei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.03.390_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0735-1097(01)01700-4","article-title":"Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart\u00a0Failure (REACH) study","volume":"39","author":"McCullough","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.03.390_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2023.03.390_bib3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000349966","article-title":"Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI)","volume":"182","author":"McCullough","year":"2013","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.jacc.2023.03.390_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000349969","article-title":"Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI)","volume":"182","author":"Haase","year":"2013","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.jacc.2023.03.390_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10741-014-9460-9","article-title":"Chronic kidney disease and cardiovascular complications","volume":"20","author":"Di Lullo","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2023.03.390_bib6","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.2215\/CJN.02920313","article-title":"Cardiorenal syndrome: new developments in the understanding and pharmacologic management","volume":"8","author":"House","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.03.390_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2010.483","article-title":"The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report","volume":"80","author":"Levey","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2023.03.390_bib9","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.03.390_bib10","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.03.390_bib11","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2023.03.390_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2023.03.390_bib13","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/ejhf.2334","article-title":"Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2023.03.390_bib14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"McCausland","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.03.390_bib15","first-page":"489","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2023.03.390_bib16","first-page":"25","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2023.03.390_bib17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.03.390_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2022.4210","article-title":"Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial","volume":"8","author":"McCausland","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2023.03.390_bib19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2215\/CJN.14901219","article-title":"Empagliflozin and cardiovascular and kidney outcomes across kdigo risk categories: post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial","volume":"15","author":"Levin","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.03.390_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2020.06.018","article-title":"Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program","volume":"77","author":"Neuen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2023.03.390_bib21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1161\/CIRCULATIONAHA.120.051901","article-title":"Gradient of risk and associations with cardiovascular efficacy of ertugliflozin by measures of kidney function: observations from VERTIS CV","volume":"143","author":"Cherney","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.03.390_bib22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00125-022-05694-6","article-title":"Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial","volume":"65","author":"Waijer","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2023.03.390_bib23","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.03.390_bib24","doi-asserted-by":"crossref","unstructured":"Packer M. Pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure. Circ Heart Fail. 2021;14(6):e008537. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008537.","DOI":"10.1161\/CIRCHEARTFAILURE.121.008537"},{"key":"10.1016\/j.jacc.2023.03.390_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for\u00a0clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723050805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723050805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:56:10Z","timestamp":1760018170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723050805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":24,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0735109723050805"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.03.390","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Empagliflozin in Patients With\u00a0Heart\u00a0Failure Across Kidney Risk\u00a0Categories","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.03.390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}